Abstract:Background: Evidence-based treatment decisions in medicine are made founded on population-level evidence obtained during randomized clinical trials. In an era of personalized medicine, these decisions should be based on the predicted benefit of a treatment on a patient-level. Survival prediction models play a central role as they incorporate the time-to-event and censoring. In medical applications uncertainty is critical especially when treatments differ in their side effect profiles or costs. Additionally, models must be adapted to local populations without diminishing performance and often without the original training data available due to privacy concern. Both points are supported by Bayesian models-yet they are rarely used. The aim of this work is to evaluate Bayesian parametric survival models on public datasets including cardiology, infectious diseases, and oncology. Materials and methods: Bayesian parametric survival models based on the Exponential and Weibull distribution were implemented as a Python package. A linear combination and a neural network were used for predicting the parameters of the distributions. A superiority design was used to assess whether Bayesian models are better than commonly used models such as Cox Proportional Hazards, Random Survival Forest, and Neural Network-based Cox Proportional Hazards. In a secondary analysis, overfitting was compared between these models. An equivalence design was used to assess whether the prediction performance of Bayesian models after model updating using Bayes rule is equivalent to retraining on the full dataset. Results: In this study, we found that Bayesian parametric survival models perform as good as state-of-the art models while requiring less hyperparameters to be tuned and providing a measure of the uncertainty of the predictions. In addition, these models were less prone to overfitting. Furthermore, we show that updating these models using Bayes rule yields equivalent performance compared to models trained on combined original and new datasets. Conclusions: Bayesian parametric survival models are non-inferior to conventional survival models while requiring less hyperparameter tuning, being less prone to overfitting, and allowing model updating using Bayes rule. Further, the Bayesian models provide a measure of the uncertainty on the statistical inference, and, in particular, on the prediction.

BITES: Balanced Individual Treatment Effect for Survival data

Dynamic treatment effect phenotyping through functional survival analysis

Unbiased Prediction and Feature Selection in High-Dimensional Survival Regression

The Predictive Individual Effect for Survival Data

Estimating the Individual Treatment Effect on Survival Time Based on Prior Knowledge and Counterfactual Prediction

Estimand-based Inference in Presence of Long-Term Survivors

Evaluating the Effectiveness of Personalized Medicine With Software

Determining Individual Suitability for Neoadjuvant Systemic Therapy in Breast Cancer Patients Through Deep Learning

Doubly robust estimation of optimal treatment regimes for survival data using an instrumental variable

Personalized Dynamic Treatment Regimes in Continuous Time: A Bayesian Approach for Optimizing Clinical Decisions with Timing

Bayesian parametric models for survival prediction in medical applications

Targeted Estimation of Heterogeneous Treatment Effect in Observational Survival Analysis

Estimating optimal treatment regimes in survival contexts using an instrumental variable

Estimation in optimal treatment regimes based on mean residual lifetimes with right-censored data

Enabling Counterfactual Survival Analysis with Balanced Representations

Matching methods for obtaining survival functions to estimate the effect of a time-dependent treatment

DeepRite: Deep Recurrent Inverse TreatmEnt Weighting for Adjusting Time-varying Confounding in Modern Longitudinal Observational Data

Doubly Robust Targeted Estimation of Conditional Average Treatment Effects for Time-to-event Outcomes with Competing Risks

Optimality of testing procedures for survival data

Optimal Statistical Inference for Individualized Treatment Effects in High-dimensional Models

Individual Patient Data Meta-Analysis of Survival Data Using Poisson Regression Models